OrbiMed’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.6M | Hold |
1,018,734
| – | – | 0.34% | 50 |
|
|
2025
Q1 | $10.4M | Hold |
1,018,734
| – | – | 0.25% | 60 |
|
|
2024
Q4 | $16.1M | Hold |
1,018,734
| – | – | 0.33% | 58 |
|
|
2024
Q3 | $59.2M | Sell |
1,018,734
-250,000
| -20% | -$14.5M | 1.07% | 27 |
|
|
2024
Q2 | $58M | Hold |
1,268,734
| – | – | 1.14% | 26 |
|
|
2024
Q1 | $84M | Hold |
1,268,734
| – | – | 1.54% | 22 |
|
|
2023
Q4 | $50.4M | Sell |
1,268,734
-246,000
| -16% | -$9.78M | 1.01% | 35 |
|
|
2023
Q3 | $48.3M | Hold |
1,514,734
| – | – | 1.03% | 34 |
|
|
2023
Q2 | $60.9M | Sell |
1,514,734
-164,683
| -10% | -$6.62M | 1.1% | 35 |
|
|
2023
Q1 | $71.7M | Hold |
1,679,417
| – | – | 1.41% | 22 |
|
|
2022
Q4 | $80.6M | Hold |
1,679,417
| – | – | 1.54% | 18 |
|
|
2022
Q3 | $63.2K | Hold |
1,679,417
| – | – | 1.17% | 29 |
|
|
2022
Q2 | $46.4K | Hold |
1,679,417
| – | – | 0.84% | 38 |
|
|
2022
Q1 | $91.3M | Hold |
1,679,417
| – | – | 1.48% | 22 |
|
|
2021
Q4 | $98.3M | Hold |
1,679,417
| – | – | 1.26% | 30 |
|
|
2021
Q3 | $66.4M | Hold |
1,679,417
| – | – | 0.73% | 43 |
|
|
2021
Q2 | $71.3M | Hold |
1,679,417
| – | – | 0.72% | 45 |
|
|
2021
Q1 | $103M | Hold |
1,679,417
| – | – | 0.97% | 30 |
|
|
2020
Q4 | $118M | Hold |
1,679,417
| – | – | 1.04% | 26 |
|
|
2020
Q3 | $64.8M | Hold |
1,679,417
| – | – | 0.81% | 36 |
|
|
2020
Q2 | $63M | Buy |
+1,679,417
| New | +$63M | 0.89% | 34 |
|